**Supplementary figure legend**

**Supplementary figure s1**. **No correlation between *Dhh* and *Gli1* expression levels in rat MPM cells.** Quantitative real time PCR showing *Dhh* and *Gli1* expression in IL45-*luc* cultured in 10% FBS/20%O2 and primary cells isolated from 3 different rats. The expression levels are normalized to tumor derived IL45-*luc*.

**Supplementary figure s2**. **Primary cells isolated from rat tumor did not response to SAG and vismodegib treatment.** Primary cells isolated from rat tumor derived from IL45-*luc* were exposed to SAG and vismodegib for 72 hours at 37ºC, 3%O2. Hh pathway target genes *Gli1* and *Ptch1* were analyzed by quantitative real time PCR.

**Supplementary figure s3. Reduced fibronectin protein levels in tumor treated with vismodegib.** Immunohistochemical staining of Fibronectin showing reduced staining intensity in treated group. (C: Control; n=6, T: Treated; n=6, Data are given in mean + SD; \*, p<0.05; \*\*; p<0.001; \*\*\*; p<0.0001)

**Supplementary figure s4. Supernatant from primary culture of rat and human MPM cells could stimulate *Gli1, Ptch1* and *Fn1* expression of NIH3T3 *in vitro*.** NIH3T3 treated with supernatant were analyzed after 72 hours incubation at 37 °C 3%O2.

**Supplementary figure s5**. **Vismodegib intereferes with Bli kinetics of IL45-*luc* *in vitro* (at high concentration) but does not interfere with *in vivo* Blimeasurement.** **a)** IL45-luc was exposed to an increasing concentration of vismodegib *in vitro* and measured for Bli kinetics for 10 minutes after the administration of luciferin (exposure time 1 minute, each bar represents each minute of Bli measurement). The interference of vismodegib on Bli kinetics was detected as of 5 µM (delayed decline phase). **b)** Bli kinetics (exposure time of 1 minute) of 2 controls and 2 vismodgeib treated rats showing no difference in the decline phase.